☆ 4.4 Article

Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Related references

Note: Only part of the references are listed.
Article Immunology

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Ronza Najjar-Debbiny et al.

Summary: This study assessed the effectiveness of Paxlovid in high-risk COVID-19 patients in real-world settings. The findings demonstrate that Paxlovid is highly effective in reducing the risk of death and severe COVID-19 in the Omicron era. The study also suggests that Paxlovid may be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease. Vaccination status did not significantly impact the effectiveness of Paxlovid.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection
Article Immunology

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19)

Sarju Ganatra et al.

Summary: In this observational analysis, treatment with nirmatrelvir plus ritonavir in nonhospitalized vaccinated patients at high risk of disease progression was associated with a significantly reduced likelihood of emergency room visits, hospitalization, or death between days 10 and 30, with no apparent increase in serious complications.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection
Article Pharmacology & Pharmacy

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Laura Vangeel et al.

Summary: Remdesivir and its parent nucleoside, molnupiravir and its parent nucleoside, and the viral protease inhibitor nirmatrelvir have equipotent antiviral activity against the ancestral SARS-CoV2 strain and the variants of concern including Omicron.

ANTIVIRAL RESEARCH (2022)

Add to Collection
Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Public, Environmental & Occupational Health

Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021

Christina Yek et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection
Article Infectious Diseases

Real-world effectiveness of early molnupiravir or nirmatrelvir- ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

Carlos K. H. Wong et al.

Summary: This retrospective cohort study evaluated the clinical and virological outcomes associated with molnupiravir or nirmatrelvir-ritonavir use in hospitalised patients with mild-to-moderate COVID-19. The results showed that recipients of oral antivirals had a lower risk of all-cause mortality, disease progression, need for oxygen therapy, and a shorter time to reaching a low viral burden. The study supports the early use of oral antivirals in this population of patients.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection
Article Medicine, General & Internal

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

Ronen Arbel et al.

Summary: The study showed that among patients aged 65 years or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir compared to those who did not. However, no evidence of benefit was found in younger adults.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.